CD47 and Integrin α4/β1 Co-modified Macrophage Membrane-coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque

Atherosclerosis is a chronic inflammatory disease and the major pathological factor of most cardiovascular diseases, leading to approximately one-third of deaths worldwide. Improving local delivery of anti-inflammatory drugs to the site of atherosclerosis has significant promise to prevent the development of atherosclerotic plaque clinically. Here, a modified macrophage membrane-coated nanoparticle drug delivery able to transport colchicine to the atherosclerotic site is reported. This hybrid system efficiently targets endothelial cells under an inflammatory environment while escaping the endocytosis of macrophages. Furthermore, the anti-inflammatory effect of the modified macrophage membrane-coated nanoparticles on foam cells is studied. In vivo, the migration of the modified macrophage membrane-coated nanoparticles to atherosclerotic lesions is confirmed in a vulnerable atherosclerotic plaque mouse model. Intravenous injections of the hybrid system successfully reduce the lipid plaque load and improve the plaque stability. Our strategy provides a potential therapeutic system for the targeted delivery of anti-inflammatory drugs to the atherosclerotic site for the treatment of atherosclerosis in cardiovascular diseases. This article is protected by copyright. All rights reserved.